Artivion (AORT) Stock Price, News & Analysis

Company Overview

Artivion, Inc. (NYSE: AORT) is a medical device company focused on products and services for cardiac and vascular surgery. The company develops, manufactures and distributes implantable devices, surgical adhesives and preserved human tissues used in the treatment of complex cardiovascular conditions.

Its product portfolio includes On-X mechanical heart valves and related repair technologies, BioGlue surgical adhesive, aortic stent grafts and other devices for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in surgical procedures.

The company was formerly known as CryoLife, Inc. and adopted the Artivion name in 2021 to reflect its broader focus on cardiovascular and aortic therapies. Based in Kennesaw, Georgia, Artivion serves hospitals, surgeons and patients in the United States and international markets. The company is led by President and Chief Executive Officer Pat Mackin.

Key Stats

• Today's Range: $21.60 to $22.72
• 50-Day Range: $21.90 to $29.22
• 52-Week Range: $19.16 to $48.25
• Volume: 559,446 shs
• Average Volume: 604,362 shs
• Market Capitalization: $1.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.83
• Consensus Rating: Moderate Buy

Artivion Stock Analysis - MarketRank™

Artivion scored higher than 72% of companies evaluated by MarketBeat, and ranked 177th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Artivion has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Artivion has a consensus price target of $44.83, representing about 101.5% upside from its current price of $22.25.

Amount of Analyst Coverage

Artivion has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 71.11%

Earnings Growth

Earnings for Artivion are expected to grow by 71.11% in the coming year, from $0.45 to $0.77 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artivion is -317.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artivion is -317.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artivion has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.19% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 5.43.

Change versus previous month

Short interest in Artivion has recently increased by 12.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artivion does not currently pay a dividend.

Dividend Growth

Artivion does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Artivion has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Artivion this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,557,366.00 in company stock.

Percentage Held by Insiders

6.30% of the stock of Artivion is held by insiders.

Percentage Held by Institutions

86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:AORT
• CIK: 784199
• Web: www.artivion.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,800
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Artivion: $44.83
• High Price Target: $50.00
• Low Price Target: $40.00
• Potential Upside/Downside: +101.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 49.44
• P/E Growth: N/A
• Net Income: $9.77 million
• Net Margins: -0.67%
• Pretax Margin: 0.47%
• Return on Equity: 6.07%
• Return on Assets: 2.93%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 3.47
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: $441.33 million
• Price / Sales: 2.46
• Cash Flow: $1.10 per share
• Price / Cash Flow: 20.25
• Book Value: $9.46 per share
• Price / Book: 2.35

Miscellaneous

• Outstanding Shares: 48,760,000
• Free Float: 45,684,000
• Market Cap: $1.08 billion
• Optionable: Optionable
• Beta: 1.23